(THE CONVERSATION) Almost 620,000 gay and bisexual men in the United States were living with HIV in 2014, and 100,000 of these men were not even aware of their infection. These men are 100 times more likely to have anal cancer than HIV-negative men who exclusively have sex with women. Yet, no national screening guidelines exist for anal cancer prevention in any population. Read More
Authors: Ashish A. Deshmukh, University of Florida; Elizabeth Chiao, Baylor College of Medicine; Jagpreet Chhatwal, Harvard Medical School , and Scott B. Cantor, The University of Texas MD Anderson Cancer Center.
This article was originally published on The Conversation. Read the original article here: http://theconversation.com/how-the-anal-cancer-epidemic-in-gay-and-bi-hiv-positive-men-can-be-prevented-80358
PCORT Alumni Inga T. Lennes, MD, MPH, MBA and Kelly E. Irwin, MD, were honored along with Carrie Lubitz, MD, MPH (and 97 others) by the Mass General Cancer Center at their annual gala.
Dr. Lennes, now Senior Vice President Performance Improvement and Service Excellence for the MGPO was honored as "a compassionate clinician and accomplished administrator". She was in the PCORT class of 2011.
Dr. Irwin, who completed her fellowship in 2017, was honored for "playing a major role in shaping the way that today's healthcare system works with cancer patients who suffer from severe mental illness".
Visit the links below to read more of their accomplishments.
ITA Senior Scientist Jagpreet Chhatwal, PhD serves and as the senior and corresponding author of a paper based on a study on the benefits of directly-acting generic drugs available in India in treating hepatitis C virus (HCV). The study found the use of such drugs increased lifespan while reducing lifetime health care costs.
"Our hypothesis was that treatment would be cost saving, given the low drug costs in India. However, we were pleasantly surprised to find that the full payback was achieved so soon after treatment," said Chhatwal, who also serves as Assistant Professor of Radiology at Harvard Medical School.
To read the entire article, visit http://health.economictimes.indiatimes.com/news/pharma/how-beneficial-are-generic-hepatitis-c-drugs-available-in-india/58734705